课题基金 / 基金详情

IMMUNOBIOLOGY OF LAK CELLS

IMMUNOBIOLOGY OF LAK CELLS
LAK 细胞的免疫生物学
批准号:
3186450
负责人:
JAMES W MIER
金额:
$24.46万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1987
资助国家:
美国
项目状态:
已结题
起止时间:
1987-02-01 至 1990-01-31

项目摘要

项目成果

JAMES W MIER的其他基金

相关文献

中文摘要
翻译
该提案将研究阿司匹林的毒性和临床疗效。 患者自体IL-2激活的淋巴细胞(LAK细胞) 晚期恶性疾病正在进行二期临床试验。这个 LAK细胞受者外周血的杀瘤活性 单个核细胞对抗自然杀伤分子耐药肿瘤细胞系, 血清IL-2和IL-2抗体水平及其他参数将 被连续监测。LAK细胞的侵袭能力 肿瘤将使用111个铟标记的细胞和 身体扫描。血清IL-1、γ-干扰素水平与肿瘤 将测定坏死因子。这些化合物的体外作用 致热细胞因子对急性时相蛋白合成的影响 培养的肝癌细胞与神经肽合成 将对下丘脑细胞进行测定。这些因素的影响 IL-2激活的细胞因子及上清液 LAK细胞受者单个核细胞和血清对体外培养的影响 将对血管内皮细胞进行研究。去唾液酸糖蛋白 它们出现在淋巴细胞表面,这是 IL-2的激活将在两个维度上表征 用花生凝集素和单抗进行免疫印迹 小鼠产生的杂交瘤产生的抗体 用亲和纯化的LAK细胞蛋白免疫。这个 这些激活抗原在受试者体内的免疫原性 LAK细胞输注将用FACS-IV确定。这 调查将确定治疗潜力和 LAK细胞治疗的毒性机制及提供 关于杀瘤淋巴细胞激活的信息。
英文摘要
This proposal will investigate the toxicity and clinical efficacy of autologous IL-2-activated lymphocytes (LAK cells) in patients with advanced malignant disease in a Phase-II clinical trial. The tumoricidal activity of the LAK cell recipients' circulating blood mononuclear cells against natural killer-resistant tumor cell lines, serum levels of IL-2 and IL-2 antibodies and other parameters will be serially monitored. The ability of LAK cells to infiltrate tumors will be determined using 111 Indium-labelled cells and body scans. Serum levels of IL-1, gamma interferon, and tumor necrosis factor will be measured. The in vitro effects of these pyrogenic cytokines on acute phase protein synthesis i cultured hepatoma cells and neuropeptide synthesis in cultured hypothalamus cells will be determined. The effects of these cytokines as well as supernatants from IL-2-activated mononuclear cells and sera from LAK cell recipients on cultured endothelial cells will be investigated. Desialated glycoproteins that appear on the surface of lymphocytes as a consequence of activation by IL-2 will be characterized in two dimensional Western blots using peanut agglutinin and with monoclonal antibodies produced by hybridomas generated from mice immunized with affinity-purified LAK cell proteins. The immunogenicity of these activation antigens in patients receiving LAK cell infusions will be determined with the FACS-IV. This investigation will determine the therapeutic potential and the mechanisms of toxicity of LAK cell treatment as well as provide information on the activation of tumoricidal lymphocytes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
P4 - Treating the P13-Kinase/AKT
Treating the P13-Kinase/AKT
Targeting Raf in Melanoma: Mechanisms for Effect & Resistance & Opportunities for
  • 批准号:
    7464270
  • 项目类别:
  • 资助金额:
    $24.92万
  • 财政年份:
    2008
  • 负责人:
    JAMES W MIER
  • 依托单位:
PHASE I CLINICAL TRIAL OF DECITABINE PRIOR TO DACARBAZINE IN ADVANCED MELANOMA